We're consulting on updated methods for our healthtech guidance, including new approaches for late-stage assessment of technologies already in widespread NHS use.
Have your say and help shape how we evaluate digital health and AI technologies⬇️
https://t.co/lBEHdQDoc6
Fab new job opportunity!! 4 1/2 year SRF/RF Statistician post to take a leading role in @NIHRresearch funded Individual Participant Data Meta-Analysis (IPDMA) of ageing research trials https://t.co/dkDkU4vc3t Joint @AUASResearch and @ComplexCTRU post, with @amanda_horler and me
We are launching a new #fundingopportunity to support the development of innovative health technologies aimed at reducing waiting times and waiting lists.
🖥️ Join our launch webinar on 8 April 2025, 3pm - 4:30pm to find out more: https://t.co/quQ6oxJzEo
🎉 Exciting news!
💻 Applications are open for UG Data Science Summer Interns @LeedsCTRU
✏️Full details https://t.co/o7lQ1nZrT3
3️⃣Three projects available with me, @lesleyfairley and @bethan_copsey
🔁 Please retweet and share with students!
Two weeks left to apply for our 3 postdoctoral positions at the interface of choice modelling, machine learning and mathematical psychology (all for 3 years). Full details at https://t.co/QMy7Orpa3A
Out now in @AACjourn, "Something for everybody? Assessing the suitability of AAC systems for children using stated preference methods" https://t.co/efTOA9lgn7
I am now gearing up to advertise for a post-doc research fellow and a PhD student linked to my NIHR Advanced Fellowship. If you think you might be interested, please do get in touch.
Available online now in The Patient! Our study linking how well people with relapsing MS' choices for hypothetical disease modifying treatments in a DCE correlate with the DMTs they take in real life https://t.co/EfhTUCacMY
On a serious note, I'm very proud of our paper here: https://t.co/h0QnyAKyTR It's the first DCE to look at how reproductive issues impact women with multiple sclerosis' preferences for disease modifying treatments, with important implications for prescribing around pregnancy.
After successfully completing a pilot phase of the new EQ-5D-5L valuation study for the UK, the data collection has been initiated and expected to end at the end of Summer 2023.
For more information about the study please visit our blog 👉https://t.co/KjshCd2lOd
#EQ5D#EQ5D5L
Out now in the European Journal of Health Economics! A paper with @Quality_Outcome, @DMeadster and @Adam_Mart1n on whether and how EQ-5D-5L valuation was affected by COVID-19.
https://t.co/HNHtK7tdqf
Intrigued by the prospect of breaking the disciplinary boundaries at the intersection of data science, economics, mathematical modelling and genetic epidemiology within an expanding national biomedical research centre? If so, this advert may be for you. We are looking for
https://t.co/i3Ozra7v95
STAR - trial of 1st line TKI cessation (vs continuous treatment) in advanced renal cell carcinoma is now out in Lancet Oncology.
One of few trials ever to include the QALY as a (co-)primary end-point
📢📢 @AUHE_Leeds are recruiting
➡️Two health economics / health data science G6-G7 positions
➡️Main focus is analysing observational datasets
➡️Working with @Beardy_Econ@srkingsbury@DMeadster@Louisa_Ells & me
Deadline 31 January https://t.co/j3JcQ8k90J
The Understanding Society Fellowship programme has just opened for applications - funding for a 12-month project with direct impact https://t.co/FT9rYEdF50